A DESCRIPTIVE OBSERVATIONAL STUDY OF DIFFERENCE OF ESTROGEN & PROGESTERONE RECEPTOR STATUS BEFORE AND AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER-Reference-Cited by-同舟云学术

A DESCRIPTIVE OBSERVATIONAL STUDY OF DIFFERENCE OF ESTROGEN & PROGESTERONE RECEPTOR STATUS BEFORE AND AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER

Published:2022-03-01 Issue: Volume: Page:1-4
ISSN:
Container-title:INDIAN JOURNAL OF APPLIED RESEARCH
language:en
Short-container-title:IJAR

Author:

Singh Amarjeet¹,Kumar Neeraj²,Bhadauria Nagendra Singh³,Sharma Raj Govind⁴,Singh Amit⁵

Affiliation:

1. Ex. Resident General Surgery S.M.S Medical College, Jaipur, 302015.

2. Assistant Professor General Surgery Government Medical College Bharatpur, 321001.

3. Associate Professor General Surgery Government Medical College Bharatpur, 321001.

4. Ex. Senior Professor Surgical Oncology S.M.S Medical College, Jaipur, 302015.

5. Associate Professor General Surgery R.V.R.S Government Medical College, Bhilwara, Rajasthan, India 311001.

Abstract

Background: Neoadjuvant chemotherapy (NACT) forms the initial modality of treatment for primarily inoperable locally advanced breast cancer (LABC). A change in hormone receptor status after NACT has important therapeutic and prognostic consequences. The primary objective of this study is to compare Hormone Receptor status before and after neoadjuvant chemotherapy (discordance). The secondary objective is to study correlation between tumour response and hormone receptor expression. Method: This is a descriptive study of 80 LABC patients who received NACT. All patients who underwent core biopsy and ER/PR assessment before and after NACT were included in this study. Data was collected prospectively from each patient in a structured proforma Results and conclusion: The hormone receptor discordance rate & response to NACT was assessed. ER discordance is 16.4%. in 07 patients estrogen receptor(ER) change positive to negative and in 04patients estrogen receptor change negative to positive. PR discordance is 22.4%. In 12 patients Progesterone receptor (PR) change positive to negative and in 03patients progesterone receptor change negative to positive.

Publisher

World Wide Journals

Reference19 articles.

1. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359– 86.

2. Siegel RL; Miller KD; Jemal A CA Cancer J Clin. 2017; 67(1):7-30 (ISSN: 1542-4863)

3. Shreshtha Malvia 1, Sarangadhara Appalaraju Bagadi 1, Uma S Dubey 2, Sunita Saxena 1 Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017 Aug;13(4):289-295.doi: 10.1111/ajco.12661.

4. Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF. Hormone receptor status of breast cancer in India: a study of 798 tumors. Breast. 2000; 9:267– 270. doi: 10.1054/brst.2000.0134

5. Rampaul RS, Pinder SE, Elaston CW, Ellis IO,. Prognostic and Predictive Factors in primary breast cancer and their role in patient. Eur J Surg Oncol. 2001 Apr;27(3):229-38.